Concepedia

Reid W. Merryman

RW

Statistics

Publications

31

Citations

1.7K

H-Index

19

Active since

2011

Affiliations

Dana-Farber Cancer Institute(Current)

Memorial Sloan Kettering Cancer Center

Massachusetts General Hospital

Beth Israel Deaconess Medical Center

The University of Texas MD Anderson Cancer Center

Reid W. Merryman is an author at Dana-Farber Cancer Institute specializing in immunotherapy, oncology, and cancer immunotherapy.

Publications per year

2011–2025

31

Publications

31

PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD

Bradley M. Haverkos, Diana Abbott, Mehdi Hamadani et al. · Blood · 2017 · 242 citations · Full text

Medicine, Hematology, Oncology +17

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma

Reid W. Merryman, Haesook T. Kim, Pier Luigi Zinzani et al. · Blood · 2017 · 236 citations · Full text

Medicine, Hematology, Immunology +16

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation

Alex F. Herrera, Matthew Mei, Lawrence K. Low et al. · Journal of Clinical Oncology · 2016 · 187 citations · Full text

Medicine, Oncology, Hematologic Oncology +13

PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation

Philippe Armand, Yi‐Bin Chen, Robert Redd et al. · Blood · 2019 · 186 citations · Full text

Life Sciences, Immunology, Oncology +16

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

Mazyar Shadman, Marcelo C. Pasquini, Kwang Woo Ahn et al. · Blood · 2021 · 110 citations · Full text

Life Sciences, Hematology, Immunology +13

1–5 of 31